Compositions and methods for inhibiting gene expression of factor XII
US10308941B2 · kind B2 · utility
3Cited by
5References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 26, 2017 |
| Grant date | Jun 4, 2019 |
| Priority date | — |
| Expiry date | Sep 26, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
RNA interference (RNAi) triggers for inhibiting the expression of Factor XII (F12) gene through the mechanism of RNA interference are described. Pharmaceutical compositions comprising one or more F12 RNAi triggers together with one or more excipients capable of delivering the RNAi trigger(s) to a liver cell in vivo are also described. Delivery of the F12 RNAi trigger(s) to liver cells in vivo provides for inhibition of F12 gene expression and treatment of angioedema, including hereditary angioedema (HAE) and venous thromboembolism (VTE), and diseases associated with angioedema.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.